Novavax (NASDAQ: NVAX) reported Q4 EPS of ($0.51), $0.09 better than the analyst estimate of ($0.60). Revenue for the quarter came in at $88.31 million versus the consensus estimate of $102.74 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.